Bone Biologics Corp
For the period ended Dec 31, 2023. Filed Feb 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 21, 2024
BBLG$0.33-0.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, 2023 | December 31, 2022 | |
|---|---|---|
| Assets | ||
| Current Assets | ||
| Cash | $3,026,569 | $7,538,312 |
| Advances on research and development contract services | 328,844 | 579,910 |
| Prepaid insurance | 372,350 | 364,536 |
| Prepaid expenses | 10,000 | 12,479 |
| Total current assets | $3,737,763 | $8,495,237 |
| Total assets | $3,737,763 | $8,495,237 |
| Liabilities and Stockholders’ Equity | ||
| Current Liabilities | ||
| Accounts payable and accrued expenses | $360,662 | $104,786 |
| Research and development contract liabilities | - | 783,675 |
| Accrued legal settlement | 414,989 | - |
| Warrant liability | 55,751 | 1,659,468 |
| Total current liabilities | 831,402 | 2,547,929 |
| Total liabilities | 831,402 | 2,547,929 |
| Commitments and Contingencies | - | - |
| Stockholders’ Equity | ||
| Preferred Stock, $0.001 par value per share; 20,000,000 shares authorized; none issued or outstanding at December 31, 2023 and 2022 | - | - |
| Common stock, $0.001 par value per share; 100,000,000 shares authorized; 534,238 and 63,820 shares issued and outstanding at December 31, 2023 and 2022, respectively | 534 | 64 |
| Additional paid-in capital | 83,814,785 | 77,907,471 |
| Accumulated deficit | (80,908,958) | (71,960,227) |
| Total stockholders’ equity | 2,906,361 | 5,947,308 |
| Total liabilities and stockholders’ equity | $3,737,763 | $8,495,237 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.